Influenza Treatment Market Updates : to Surpass USD 1.2 Billion, by 2026 ; Oseltamivir Phosphate Segment Dominated the Market

Allied Market Research recently published a report, titled, "Influenza Treatment Market by Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Others), Global Opportunity Analysis and Industry Forecast, 2019-2026". According to the report, the global influenza treatment industry was pegged at $861.5 million in 2018, and is projected to hit $1.22 billion by 2026, growing at a CAGR of 4.5% from 2019 to 2026.

𝑴𝒂𝒋𝒐𝒓 𝒅𝒓𝒊𝒗𝒆𝒓𝒔 𝒇𝒐𝒓 𝒕𝒉𝒆 𝒎𝒂𝒓𝒌𝒆𝒕 𝒈𝒓𝒐𝒘𝒕𝒉
The global influenza treatment market has witnessed a surge in cases worldwide, accompanied by increased healthcare spending and research investments for novel drug development. Yet, the market faces challenges due to the availability of alternative treatments. Nonetheless, promising growth prospects in developing nations offer lucrative opportunities ahead.

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝑹𝒆𝒑𝒐𝒓𝒕 𝒂𝒕:
https://www.alliedmarketresearch.com/request-sample/6471

𝑶𝒔𝒆𝒍𝒕𝒂𝒎𝒊𝒗𝒊𝒓 𝑷𝒉𝒐𝒔𝒑𝒉𝒂𝒕𝒆 𝒔𝒆𝒈𝒎𝒆𝒏𝒕 𝒅𝒐𝒎𝒊𝒏𝒂𝒕𝒆𝒅 𝒕𝒉𝒆 𝒎𝒂𝒓𝒌𝒆𝒕
In 2018, the oseltamivir phosphate segment dominated the global influenza treatment market, holding over two-fifths of the market share based on type. This dominance is attributed to the recommendation by the CDC and the American Academy of Pediatrics (AAP) for early flu treatment across all age groups, driving segment growth. However, the baloxavir marboxil segment is anticipated to witness the highest compound annual growth rate (CAGR) of 4.6% during the forecast period. Baloxavir marboxil demonstrates efficacy against influenza A strains resistant to oseltamivir, positioning it as a preferred treatment option and consequently fueling segment growth.

𝑻𝒉𝒆 𝒓𝒆𝒕𝒂𝒊𝒍 𝒑𝒉𝒂𝒓𝒎𝒂𝒄𝒚 𝒔𝒆𝒈𝒎𝒆𝒏𝒕 𝒕𝒐 𝒎𝒂𝒏𝒊𝒇𝒆𝒔𝒕 𝑪𝑨𝑮𝑹 𝒕𝒉𝒓𝒐𝒖𝒈𝒉 2026
In terms of distribution channel, the retail pharmacy segment is expected to witness the most significant compound annual growth rate (CAGR) of 4.7% throughout the forecast period. Furthermore, this segment secured the leading position in 2018, capturing almost half of the global influenza treatment market. This dominance can be attributed to the widespread presence of retail pharmacies worldwide and the convenience they provide. The study also evaluates other segments such as hospital pharmacy and others.

𝑵𝒐𝒓𝒕𝒉 𝑨𝒎𝒆𝒓𝒊𝒄𝒂 𝒉𝒆𝒍𝒅 𝒕𝒉𝒆 𝒍𝒊𝒐𝒏'𝒔 𝒔𝒉𝒂𝒓𝒆
In 2018, North America dominated the market, accounting for approximately one-third of the total market share, primarily due to a surge in influenza infections in the region. However, the Asia-Pacific region is expected to exhibit the fastest compound annual growth rate (CAGR) of 5.6% during the forecast period. This is attributed to an increase in awareness regarding early diagnosis for more effective treatment of the medical condition.

𝑭𝒐𝒓 𝑷𝒖𝒓𝒄𝒉𝒂𝒔𝒆 𝑬𝒏𝒒𝒖𝒊𝒓𝒚 𝒂𝒕
: https://www.alliedmarketresearch.com/purchase-enquiry/6471

𝑴𝒂𝒋𝒐𝒓 𝒎𝒂𝒓𝒌𝒆𝒕 𝒑𝒍𝒂𝒚𝒆𝒓𝒔
AstraZeneca Plc
BioCryst Pharmaceuticals, Inc.
Daiichi Sankyo Company Limited
F. Hoffmann-La Roche AG
GlaxoSmithKline Plc
Mylan N.V
Natco Pharma Limited
Novartis AG
Sanofi
Teva Pharmaceutical Industries Limited

𝑲𝑬𝒀 𝑩𝑬𝑵𝑬𝑭𝑰𝑻𝑺 𝑭𝑶𝑹 𝑺𝑻𝑨𝑲𝑬𝑯𝑶𝑳𝑫𝑬𝑹𝑺
This report entails a detailed quantitative analysis along with the global influenza treatment market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The influenza treatment market forecast is studied from 2018 to 2026.
The market size and estimations are based on a comprehensive analysis of key developments in the influenza treatment industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the influenza treatment market

𝑲𝑬𝒀 𝑭𝑰𝑵𝑫𝑰𝑵𝑮𝑺 𝑶𝑭 𝑻𝑯𝑬 𝑺𝑻𝑼𝑫𝒀
• Oseltamivir phosphate occupied more than two-fifth share of the global influenza treatment market in 2018.
• The others segment in distribution channel pharmacy segment is anticipated to grow with the highest CAGR throughout the forecast period.
• The others segment in product type accounted for more than two-fifth share of the market in 2018.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

𝑲𝒏𝒐𝒘 𝑴𝒐𝒓𝒆- https://www.alliedmarketresearch.com/influenza-treatment-market-A06106

𝑶𝒕𝒉𝒆𝒓 𝑻𝒓𝒆𝒏𝒅𝒊𝒏𝒈 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝑫𝒐𝒎𝒂𝒊𝒏
𝑻𝒓𝒂𝒖𝒎𝒂 𝑰𝒎𝒑𝒍𝒂𝒏𝒕𝒔 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/trauma-implants-market-A17527

𝑵𝒆𝒐𝒏𝒂𝒕𝒂𝒍 𝑰𝒏𝒕𝒆𝒏𝒔𝒊𝒗𝒆 𝑪𝒂𝒓𝒆 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/neonatal-intensive-care-market-A17086

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.